stoxline Quote Chart Rank Option Currency Glossary
  
Invitae Corporation (NVTA)
0.019  -0.011 (-35.59%)    02-14 15:59
Open: 0.0172
High: 0.024
Volume: 22,459,258
  
Pre. Close: 0.0295
Low: 0.016
Market Cap: 5(M)
Technical analysis
2024-05-30 4:43:26 PM
Short term     
Mid term     
Targets 6-month :  0.01 1-year :  0.02
Resists First :  0.01 Second :  0.01
Pivot price 0
Supports First :  0 Second :  0
MAs MA(5) :  0 MA(20) :  0
MA(100) :  0.28 MA(250) :  0.72
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  18.9 D(3) :  8.5
RSI RSI(14): 34.5
52-week High :  1.66 Low :  0
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ NVTA ] has closed below upper band by 41.4%. Bollinger Bands are 88.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 33 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.01 - 0.01 0.01 - 0.01
Low: 0 - 0 0 - 0
Close: 0.01 - 0.01 0.01 - 0.01
Company Description

Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

Headline News

Tue, 28 May 2024
Invitae (NVTA) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Movies Canada

Sun, 26 May 2024
Genetic Testing Likely to Drive Invitae's (NVTA) Q1 Earnings - Yahoo Lifestyle UK

Sat, 25 May 2024
What Type Of Shareholders Make Up Invitae Corporation's (NYSE:NVTA) Share Registry? - Yahoo Movies Canada

Wed, 24 Apr 2024
Invitae Enters into Agreement with Labcorp for Sale of Business - PR Newswire

Tue, 13 Feb 2024
Invitae Files for Voluntary Chapter 11 Protection; Pursues Sale Process - PR Newswire

Mon, 05 Feb 2024
SoftBank-Backed Genetic Testing Invitae's Descent from $7B Valuation to Near-Bankruptcy - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NYSE
Sector:
Healthcare
Industry:
Medical - Diagnostics & Research
Shares Out 286 (M)
Shares Float 284 (M)
Held by Insiders 1.5 (%)
Held by Institutions 47.9 (%)
Shares Short 67,760 (K)
Shares Short P.Month 59,350 (K)
Stock Financials
EPS -5.37
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -3.78
Profit Margin -299.2 %
Operating Margin -84.9 %
Return on Assets (ttm) -23.8 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth -9.2 %
Gross Profit (p.s.) 0
Sales Per Share 1.68
EBITDA (p.s.) -1.24
Qtrly Earnings Growth 0 %
Operating Cash Flow -238 (M)
Levered Free Cash Flow -35 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value -0.01
Price to Sales 0
Price to Cash Flow -0.02
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android